A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
Actinic Keratosis
DRUG: PEP005 (Ingenol Mebutate) gel, 0.015%|DRUG: Vehicle Gel
Complete Clearance of Actinic Keratoses (AK) Lesions, Complete clearance of the treatment field, baseline and 57 days
Partial Clearance of Actinic Keratoses (AK), Partial clearance defined as â‰¥ 75% reduction in the number of AK lesions identified at baseline in the treatment area, baseline and 57 days
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.